Redmile Group, LLC Viking Therapeutics, Inc. Transaction History
Redmile Group, LLC
- $952 Million
- Q1 2025
Shares
3 transactions
Others Institutions Holding VKTX
# of Institutions
432Shares Held
65.2MCall Options Held
8.28MPut Options Held
3.39M-
Vanguard Group Inc Valley Forge, PA10.2MShares$285 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$169 Million0.01% of portfolio
-
State Street Corp Boston, MA4.06MShares$114 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY3.13MShares$87.6 Million0.01% of portfolio
-
Morgan Stanley New York, NY3.12MShares$87.4 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.15B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...